You are here: Industry Insights > Jyseleca

News List

Galapagos’ Jyseleca gets UK marketing authorization for ulcerative colitis drugs.com
January 19, 2022
Galapagos has obtained marketing authorization from the UK Medicines and Healthcare products Regulatory...
NICE publishes final guidance backing Jyseleca for rheumatoid arthritis pharmatimes
January 22, 2021
The National Institute for Health and Care Excellence (NICE) has published its final appraisal determination (FAD) recommending the use of Gilead Sciences and Galapagos’ Jyseleca (filgotinib) for the treatment of rheumatoid arthritis (RA).
Gilead, Galapagos amend commercialisation and development pact for Jyseleca (filgotinib) expresspharma
December 16, 2020
Under the new arrangement, Galapagos will assume sole responsibility in Europe for filgotinib in RA, Gilead to receive royalties on European sales starting in 2024.
Gilead’s oral JAK inhibitor filgotinib wins EU approval pharmatimes
September 30, 2020
Gilead Science’s Galapagos-partnered oral JAK inhibitor filgotinib has been approved by the European Commission under the brand name Jyseleca for the treatment of moderate-to-severe active rheumatoid arthritis (RA).
Gilead gets approval for Jyseleca (filgotinib) in Japan for rheumatoid arthritis expresspharma
September 27, 2020
Gilead Japan will hold marketing authorisation of Jyseleca in Japan while Eisai will be responsible for product distribution.